Evolus, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Newport Beach, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $297 million and a loss of $52 million (its filed statements).
Product businessPharmaceutical PreparationsNewport Beach, CAfilings since 20138 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.1 out of ten, 8 of 9 metrics filed and 1 estimated: past 7.2 out of ten, present 6.3 out of ten, future 4.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 7.0 out of ten. 8 filed years; profitable in 0 of 8. 70th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 6.2 out of ten. CrossAssetData estimate 6.2/10, confidence 35 of 100 (one part). 62nd percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 6.0 out of ten. Leverage 110%: owes 110¢ per asset dollar. 60th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 7.1 out of ten. top 29% of 314 in its family; net margin -17.4%. 71st percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.7 out of ten. top 43% of 315 in its family for leadership; chief executive since 2018. 57th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 2.8 out of ten. bottom 28% of 272 in its family for room to expand. 28th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 7.2 out of ten. top 28% of 307 in its family for growth drivers. 72nd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 4.5 out of ten. bottom 46% of 234 in its family for expectations against reality. 46th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-03 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-09-04. Filings on record since 2013. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Product 99%, Service 1%. As tagged in its annual report (Form 10-K, filed 2026-03-03).
Who runs it
Moatazedi, David (President and Chief Executive Officer); Mitchell, Tatjana (Chief Financial Officer); Avelar, Rui (Chief Medical Officer and Head of Research & Development); Yamagishi-Dressler, Tomoko (Chief Marketing Officer); Gill, David N (director); Malik, Vikram (director); Parschauer, Karah Herdman (director); Stewart, Brady (director); White, Albert G III (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.